Advanced Cell Technology (ACTC)

Advanced Cell Technology, Inc. is a biotechnology company that specializes in the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. The company applies stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to the bedside.

The Company is in the final stages of moving toward the initiation of Phase I clinical trials for its Retinal Pigment Epithelial (RPE) program which addresses a number of retinal degenerative disorders. ACT has published positive data from animal studies for the RPE cell program – completed in collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU) – as well as recently announced promising results – also in collaboration with OHSU- from GLP Safety Studies and long-term efficacy studies for the RPE therapy. Currently ACT is finalizing preclinical studies for the bio-distribution of RPE and expects spiking studies to be finished in the second half of 2009. ACT expects to file the RPE program IND by the end of the year. Advanced Cell also has moved forward rapidly with it Hemangioblast (HG) platform. ACT has published positive data in the journal NATURE Methods for its HG cellular program for the treatment of blood and cardiovascular diseases. Additionally the company’s Myoblast program is an autologous adult stem cell therapy for the treatment of heart disease. The Myoblast program has successfully completed four Phase I clinical trials and has clearance from the FDA to begin Phase II trials.

In recent years ACT has announced the successful development of a novel technique to generate embryonic stem cell lines without destroying embryos, a breakthrough in the ethical debate surrounding the industry. Since then, the company has announced on multiple occasions the successful creation of human embryonic stem cell lines without the destruction or disruption of the developmental potential of the embryos. In support of its research and applications Advanced Cell owns or licenses over 380 patents and patent applications.

ACT is focused on three product areas.

1) The retinal pigment epithelium (RPE) program, which they believe will yield new therapies for treating disease indications and disorders such as age-related macular degeneration (AMD). The first therapeutic treatment using RPE therapy will be a treatment for Stargardt’s Disease. Along with our collaborators at the Casey Eye Institute at OHSU, the Company just announced a successful study results supporting the long-term safety and efficacy of our Retinal Disease therapy. ACT expects to file an IND by the end of 2009

2) The hemangioblast (HG) cell program could yield novel therapies for cardiac diseases such as heart failure has successfully completed Phase I human clinical trials. The program has clearance from the FDA to begin Phase II human clinical trials and ACT is currently seeking funding to support the initiation of a Phase II clinical trial.

3) The myoblast program which could yield novel therapies for cardiac diseases such as heart failure. It has successfully completed Phase I human clinical trials, and the program has clearance from the FDA to begin Phase II human clinical trials, ACT is currently seeking funding to support the initiation of a Phase II clinical trial.

Advanced Cell is led by an experienced management team and world-class scientific team, including CEO William Caldwell, Chief Scientific Officer Robert Lanza M.D., VP of Regulatory Ed Mickunas, Senior Director of Manufacturing Roger Gay PhD and our Director of Operations Rita Parker. The company operates a GMP-capable laboratory in Massachusetts and maintains offices in Southern California.